Moleculin's AML Trial Shows a Threefold Interim Remission Advantage - But the Definitive Readout Is Still Ahead

Moleculin's AML Trial Shows a Threefold Interim Remission Advantage - But the Definitive Readout Is Still Ahead

Moleculin's interim MIRACLE data shows 43% and 36% complete remission in relapsed/refractory AML versus 12% for control - but the 90-patient readout is still months away.